MET and lung cancer: Moreover, studies have demonstrated that PHA-665752 (PHA), another selective and ATP-competitive c-Met inhibitor, weakens c-Met-mediated growth, motility, invasion, and morphology of ovarian, stomach, and lung cancers [9,10,20].